These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12517247)

  • 21. Eprosartan.
    McClellan KJ; Balfour JA
    Drugs; 1998 May; 55(5):713-8; discussion 719-20. PubMed ID: 9585867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines?
    Rupp H
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S25-9. PubMed ID: 18093411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study.
    Punzi HA; Punzi CF
    J Hum Hypertens; 2004 Sep; 18(9):655-61. PubMed ID: 15042114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eprosartan: an angiotensin-II receptor antagonist for the management of hypertension.
    Cheng-Lai A
    Heart Dis; 2002; 4(1):54-9. PubMed ID: 11975834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
    Makris TK; Stavroulakis G; Papadopoulos DP; Krespi P; Hatzizacharias A; Zilidis A; Tsoukala C; Votteas VE
    Drugs Exp Clin Res; 2004; 30(3):125-32. PubMed ID: 15366789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
    Ram CV; Rudmann MA
    Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1003-11. PubMed ID: 18035916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality of life and cough on antihypertensive treatment: a randomised trial of eprosartan, enalapril and placebo.
    Rake EC; Breeze E; Fletcher AE
    J Hum Hypertens; 2001 Dec; 15(12):863-7. PubMed ID: 11773989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of long-term eprosartan versus enalapril antihypertensive therapy on left ventricular mass and coronary flow reserve in stage I-II hypertension. Eprosartan Study Group.
    Diamond JA; Gharavi A; Roychoudhury D; Machac J; Henzlova MJ; Travis A; Phillips RA
    Curr Med Res Opin; 1999; 15(1):1-8. PubMed ID: 10216805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin blockade with eprosartan: vascular and functional implications.
    Ram CV
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S5-11. PubMed ID: 18093408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation).
    Rahman ST; Lauten WB; Khan QA; Navalkar S; Parthasarathy S; Khan BV
    Am J Cardiol; 2002 Mar; 89(6):686-90. PubMed ID: 11897210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group.
    Gavras I; Gavras H
    Curr Med Res Opin; 1999; 15(1):15-24. PubMed ID: 10216807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eprosartan mesylate effectively reduces systolic and diastolic blood pressure in a Canadian primary care setting.
    Conter HS; McKay DW; Reiz RJ
    Can J Cardiol; 2004 Oct; 20 Suppl C():6C-10C. PubMed ID: 16807617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension.
    Sachse A; Verboom CN; Jäger B
    J Hum Hypertens; 2002 Mar; 16(3):169-76. PubMed ID: 11896506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of isosorbide mononitrate and AII inhibition on pulse wave reflection in hypertension.
    Stokes GS; Barin ES; Gilfillan KL
    Hypertension; 2003 Feb; 41(2):297-301. PubMed ID: 12574098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of treatment with eprosartan on pulse pressure: factors predicting response.
    de la Sierra A; Muñoz A; Arcos E; López JS; Relats J;
    Can J Cardiol; 2004 Oct; 20 Suppl C():17C-22C. PubMed ID: 16807619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure.
    Brooks DP; Ruffolo RR
    J Hypertens Suppl; 1999 Jun; 17(2):S27-32. PubMed ID: 10465064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of eprosartan and enalapril in the treatment of black hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group.
    Levine B
    Curr Med Res Opin; 1999; 15(1):25-32. PubMed ID: 10216808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Antihypertensive treatment with eprosartan mesilate of patients in acute and late periods of ischemic stroke].
    Gusev EI; Martynov MIu; Boĭko AN; Petukhov EB; Makarov AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(11):15-20. PubMed ID: 14681960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. The Eprosartan Multinational Study Group.
    Hedner T; Himmelmann A
    J Hypertens; 1999 Jan; 17(1):129-36. PubMed ID: 10100104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eprosartan dual action offers clinical benefit for elderly and overweight hypertensives.
    Cardiovasc J S Afr; 2004; 15(2):91-2. PubMed ID: 15148545
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.